Edition:
United Kingdom

People: ContraVir Pharmaceuticals Inc (CTRV.OQ)

CTRV.OQ on NASDAQ Stock Exchange Capital Market

0.11USD
24 May 2019
Change (% chg)

$-0.02 (-14.81%)
Prev Close
$0.13
Open
$0.12
Day's High
$0.13
Day's Low
$0.11
Volume
655,046
Avg. Vol
664,787
52-wk High
$2.56
52-wk Low
$0.10

Adams, Thomas 

Dr. Thomas H. Adams, Jr., Ph.D., is Independent Director of the Company. Dr. Adams has been Chairman of the Board of Trovagene, Inc., a precision medicine company, since April 2009. Dr. Adams has served as the Chairman of Clearbridge BioPhotonics, Inc., an imaging solutions company, since April 2013. From June 2005 through 2011, Dr. Adams served as a director of IRIS International, Inc., a diagnostics company, and has served as Chief Technology Officer of IRIS since April 2006. Dr. Adams was the Head of Iris Molecular Diagnostics from 2006 until November 2012 and has served as the President of Iris Personalized Medicine since 2011. In November 2012, IRIS was acquired by Danaher Corporation. Dr. Adams served as Chairman and Chief Executive Officer of Leucadia Technologies, a privately held medical-device company, from 1998 to April 2006, when Leucadia was acquired by IRIS. In 1989, Dr. Adams founded Genta, Inc., a publicly held biotechnology company in the field of antisense technology, and served as its Chief Executive Officer until 1997. Dr. Adams founded Gen-Probe, Inc. in 1984 and served as its Chief Executive Officer and Chairman until its acquisition by Chugai Biopharmaceuticals, Inc. in 1989. Dr. Adams has served as a director of Synergy Pharmaceuticals Inc., a biotechnology company, since July 2009. Dr. Adams holds a Ph.D. in Biochemistry from the University of California, at Riverside. The Board believes that Dr. Adams’ executive leadership, particularly in the diagnostic field, and the extensive healthcare expertise he has developed qualifies Dr. Adams to serve as a director of our Company.

Basic Compensation

Total Annual Compensation, USD 27,250
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 34,717
Fiscal Year Total, USD 61,967

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --